OncoMatch/Clinical Trials/NCT06584227
Adebrelimab and Chidamide for Pancreatic Cancer
Is NCT06584227 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Adebrelimab and Chidamide Combined with Gemcitabine and S1 for pancreatic cancer, adult.
Treatment: Adebrelimab and Chidamide Combined with Gemcitabine and S1 — Pancreatic cancer is a kind of digestive system tumor with high malignant degree and poor prognosis. Most patients with pancreatic cancer are locally advanced or have distant metastases at the time of diagnosis, so it is extremely important to find effective drugs to control tumor metastasis. The primary treatment regimen for advanced pancreatic cancer remains chemotherapy, which results in a median survival time of only 8 to 12 months. Therefore, there is an urgent need to explore new combination therapies to extend survival. Therefore, this study aims to evaluate the efficacy and safety of Adebrelimab and Chidamide in Combination with Gemcitabine and S1 as first-line treatment for locally advanced or metastatic pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Previous treatment with ICIs
Cannot have received: histone deacetylase inhibitor
Previous treatment with HDACi
Cannot have received: systemic antitumor therapy
Exception: except stent placement
have not previously received systematic antitumor therapy for the current stage of disease, including surgery (except stent placement), radiotherapy, chemotherapy, targeting, immunotherapy or investigational therapy
Cannot have received: investigational therapy
Received any other investigational drug/device treatment within 4 weeks prior to enrollment
Lab requirements
Blood counts
The function of major organs is good (no blood components, cell growth factors, whitening drugs, platelet drugs, anemia correction drugs are allowed within 14 days before enrollment)
Kidney function
The function of major organs is good
Liver function
The function of major organs is good
Cardiac function
No clinical symptoms or heart diseases that are not well controlled, such as: NYHA2 or above heart failure; unstable angina pectoris; myocardial infarction occurred within 1 year; clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention
The function of major organs is good (no blood components, cell growth factors, whitening drugs, platelet drugs, anemia correction drugs are allowed within 14 days before enrollment); Have clinical symptoms or heart diseases that are not well controlled, such as: (1)NYHA2 or above heart failure; (2) Unstable angina pectoris; (3) Myocardial infarction occurred within 1 year; (4) Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify